Other languages GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.3 ^USD	+3.29%		-1.35%	-56.86%

Mar. 26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Caterpillar deja París, el cacao está menos caliente	Apr. 30
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud	Apr. 30
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	Feb. 01
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	Nov. 06
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
GT Biopharma, Inc. Announces Board Changes	23-05-04
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
GT Biopharma to Sell 6.5 Million Shares and Warrants, Expects Gross Proceeds of $6.5 Million	22-12-30
Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer	22-12-14
GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee	22-12-13
GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to Treat Leukemia	22-12-12
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31
GT Biopharma Files $150 Million Mixed Shelf	22-10-14
GT Biopharma Taps Cytovance Biologics as Manufacturing Partner for Leukemia Drug	22-08-31
Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650	22-08-30
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Other languages

Filters